DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
QUICK SEARCH:   [advanced]


     

Drug Metabolism and Disposition Fast Forward
First published on January 28, 2008; DOI: 10.1124/dmd.107.019570

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.107.019570v1
36/4/721    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Li, W.
Right arrow Articles by Humphreys, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, W.
Right arrow Articles by Humphreys, G.


Received for publication November 5, 2007.
Revised January 23, 2008.
Accepted for publication January 24, 2008.

METABOLITE GENERATION VIA MICROBIAL BIOTRANSFORMATIONS WITH ACTINOMYCETES: RAPID SCREENING FOR ACTIVE STRAINS AND BIOSYNTHESIS OF IMPORTANT HUMAN METABOLITES OF TWO DEVELOPMENT STAGE COMPOUNDS, BMS-587101 AND DASATINIB

Wenying Li 1*, Jonathan L Josephs 1, Gary L Skiles 2, Griffith Humphreys 3

1 Bristol-Myers Squibb 2 Amgen 3 Bristol-Myers Squibb PRI

* Address correspondence to: E-mail: wenying.li{at}bms.com

Abstract

The enzymes present in many microbial strains are capable of carrying out a variety of biotransformations when presented with drug-like molecules. Although the enzymes responsible for the biotransformations are not well characterized, microbial strains can often be found that produce metabolites identical to those found in mammalian systems. However, traditional screening for microbial strains that produce metabolites of interest is done with many labor intensive steps that include multiple shake flasks and many manual manipulations which hinder the application of these techniques in drug metabolite preparation. A 24-well microtiter plate screening system was developed for rapid screening of actinomycetes strains for their ability to produce metabolites of interest. The utility of this system was first demonstrated with the well-characterized cytochrome P450 substrate diclofenac. Subsequently the use of this system allowed the rapid identification of several actinomycetes strains that were capable of converting two drug candidates under development, BMS-587101 and dasatinib (SPRYCEL®, BMS-345825), to mammalian metabolites of interest. Milligram quantities of the metabolites were then prepared by scaling-up the microbial biotransformation reactions. These quantities were sufficient for initial characterization, such as testing for pharmacological activity, and use as analytical standards prior to the availability of authentic chemically synthesized compounds.


Key words: anticancer agents, cytochrome P450 catalyzed oxidations, drug development, drug discovery, metabolite identification, microsomes, monooxygenases, structure elucidation


This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
L. J. Christopher, D. Cui, C. Wu, R. Luo, J. A. Manning, S. J. Bonacorsi, M. Lago, A. Allentoff, F. Y. F. Lee, B. McCann, et al.
Metabolism and Disposition of Dasatinib after Oral Administration to Humans
Drug Metab. Dispos., July 1, 2008; 36(7): 1357 - 1364.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics.